A pair of new studies finds no significant benefit of the antiviral drug nirmatrelvir-ritonavir (Paxlovid) in alleviating the symptoms of adult long-COVID patients or in preventing the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback